The FDA approved the PD-1–blocking monoclonal antibody in combination with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous ce...
Patients with previously untreated BRAF V600E–mutated metastatic colorectal cancer who receive the BRAF inhibitor encorafenib and the EGFR inhibitor cetuximab plus mFOLFOX6 (modified leucovorin, fluor...
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with primary squamous cell carcinoma of the ...
New guidance positions GLP-1 and GLP-1/GIP therapies as frontline options for long-term weight management—with profound implications for cardiovascular outcomes, access equity, and chronic disease care.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
ACC statement highlights semaglutide and tirzepatide as therapies associated with improved symptoms and functional capacity in patients with heart failure with preserved ejection fraction and obesity.
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. ...
ACR/AAHKS guideline conditionally recommends against delaying total knee arthroplasty based solely on BMI, prompting debate among orthopedic specialists.